Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Honorhealth Research Institute
Scottsdale, Arizona, United States
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Los Angeles, California, United States
- Florida Cancer Specialists
Sarasota, Florida, United States
- Washington University School of Medicine, Division of Oncology
St Louis, Missouri, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2013
- Primary completion
- 30 Apr 2017
- Completion
- 30 Jun 2017
- Last update posted
- 28 Jul 2017
- Registered enrollment
- 48
- Registry id
- NCT01849744
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.